Skip to main content
ANVS
NYSE Life Sciences

Second Positive DSMB Safety Nod Keeps Phase 3 Alzheimer's Trial on Track

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$0.8
Mkt Cap
$32.009M
52W Low
$0.616
52W High
$5.5
52W Position info
30% above low
Off High info
85% below high
Rel. Volume info
1.2× avg
Market data snapshot near publication time

ANVS sits 30% above its 52-week low of $0.616.

Summary

An independent DSMB recommended that the Phase 3 DUET-AD trial of buntanetap in early Alzheimer's continue without modification after reviewing safety data through September 22, 2026, from 861 patients. It is the second consecutive positive review, following the 6-month feedback announced in February 2026. Management says detailed safety outcomes will be reported in March alongside the 6-month symptomatic results. The trial timeline holds: last patient last visit for the 6-month period expected December 31, 2026, database lock February 8, 2027, and 6-month topline results in March 2027. The readout is the binary event for a company this size, and the safety clearance at scale removes one overhang ahead of it. The company ended Q3 with $2.8 million of cash and a going-concern warning, funded by the $21.0 million November offering, so the March data is what the balance sheet is now riding on.

At the time of this announcement, ANVS was trading at $0.80 on NYSE in the Life Sciences sector, with a market capitalization of approximately $32M. The 52-week trading range was $0.62 to $5.50. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

ANVS - Latest Insights

ANVS
Nov 13, 2026, 4:24 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.940
Real-time Price: $0.780 info
Change: -$0.160 (-17%) info
Market Cap: $32.009M info
ANVS
Nov 06, 2026, 4:30 PM EST
Filing Type: 4
Importance Score:
8
Price at Filing: $0.8799
Real-time Price: $0.780 info
Change: -$0.0999 (-11%) info
Market Cap: $32.009M info
ANVS
Nov 05, 2026, 8:05 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $0.8689
Real-time Price: $0.780 info
Change: -$0.0889 (-10%) info
Market Cap: $32.009M info
ANVS
Nov 04, 2026, 5:01 PM EST
Filing Type: 424B5
Importance Score:
8
Price at Filing: $0.940
Real-time Price: $0.780 info
Change: -$0.160 (-17%) info
Market Cap: $32.009M info
ANVS
Nov 04, 2026, 4:07 PM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $0.8507
Real-time Price: $0.780 info
Change: -$0.0707 (-8%) info
Market Cap: $32.009M info